(BMI) Badger Meter - Ratings and Ratios
Meters, Valves, Sensors, Software
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.74% |
| Yield on Cost 5y | 1.50% |
| Yield CAGR 5y | 18.13% |
| Payout Consistency | 97.1% |
| Payout Ratio | 31.5% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 31.0% |
| Value at Risk 5%th | 47.5% |
| Relative Tail Risk | -6.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.57 |
| Alpha | -35.49 |
| CAGR/Max DD | 0.43 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.256 |
| Beta | 0.908 |
| Beta Downside | 0.670 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.49% |
| Mean DD | 10.29% |
| Median DD | 6.98% |
Description: BMI Badger Meter January 07, 2026
Badger Meter Inc. (NYSE:BMI) designs, manufactures, and markets flow-measurement and water-smart-metering solutions for municipal utilities, industrial users, and OEMs. Its product portfolio spans flow meters, valves, optical and electrochemical water-quality sensors, high-frequency pressure and leak-detection devices, and the BEACON cloud-based software suite that delivers alerts and consumer-engagement tools. Sales are executed both directly and through a network of distributors and OEM representatives, serving sectors such as water/wastewater, HVAC, and corporate sustainability.
Key recent metrics (FY 2023) include approximately $1.1 billion in revenue, a 5 % year-over-year growth rate, and an operating margin near 12 %. The company’s backlog of recurring smart-metering contracts exceeded $300 million, reflecting strong demand driven by U.S. water-infrastructure spending, which the American Water Works Association estimates will total roughly $1 trillion over the next decade. Additionally, ESG-focused capital allocation-particularly utilities’ need to meet tightening water-conservation regulations-continues to boost adoption of Badger’s advanced metering infrastructure.
For deeper quantitative analysis, you might explore ValueRay’s platform for detailed financial metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 138.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.72 > 1.0 |
| NWC/Revenue: 37.86% < 20% (prev 49.78%; Δ -11.92% < -1%) |
| CFO/TA 0.18 > 3% & CFO 181.0m > Net Income 138.8m |
| Net Debt (-201.7m) to EBITDA (207.7m): -0.97 < 3 |
| Current Ratio: 3.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.6m) vs 12m ago 0.12% < -2% |
| Gross Margin: 41.26% > 18% (prev 0.40%; Δ 4087 % > 0.5%) |
| Asset Turnover: 101.2% > 50% (prev 100.1%; Δ 1.07% > 0%) |
| Interest Coverage Ratio: -3.28 > 6 (EBITDA TTM 207.7m / Interest Expense TTM -43.5m) |
Altman Z'' (< 1.1 .. > 2.6) 7.98
| A: 0.35 (Total Current Assets 494.6m - Total Current Liabilities 153.4m) / Total Assets 978.3m |
| B: 0.64 (Retained Earnings 624.1m / Total Assets 978.3m) |
| C: 0.16 (EBIT TTM 142.7m / Avg Total Assets 890.6m) |
| D: 2.42 (Book Value of Equity 666.4m / Total Liabilities 275.8m) |
| Altman-Z'' Score: 7.98 = AAA |
ValueRay F-Score (Strict, 0-100) 81.47
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 3.42% |
| 3. FCF Margin: 18.45% |
| 4. Debt/Equity: 0.01 |
| 5. Debt/Ebitda: -0.97 |
| 6. ROIC - WACC: 6.80% |
| 7. RoE: 21.12% |
| 8. Revenue Trend: 97.93% |
| 9. EPS Trend: 30.74% |
What is the price of BMI shares?
Over the past week, the price has changed by +0.92%, over one month by -6.01%, over three months by -5.51% and over the past year by -20.61%.
Is BMI a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BMI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 211.6 | 22.9% |
| Analysts Target Price | 211.6 | 22.9% |
| ValueRay Target Price | 178.7 | 3.8% |
BMI Fundamental Data Overview January 20, 2026
P/E Forward = 32.4675
P/S = 5.6144
P/B = 7.2019
P/EG = 3.2486
Revenue TTM = 901.1m USD
EBIT TTM = 142.7m USD
EBITDA TTM = 207.7m USD
Long Term Debt = unknown (none)
Short Term Debt = 5.35m USD (from shortTermDebt, last fiscal year)
Debt = 6.01m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -201.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.86b USD (5.06b + Debt 6.01m - CCE 201.7m)
Interest Coverage Ratio = -3.28 (Ebit TTM 142.7m / Interest Expense TTM -43.5m)
EV/FCF = 29.25x (Enterprise Value 4.86b / FCF TTM 166.3m)
FCF Yield = 3.42% (FCF TTM 166.3m / Enterprise Value 4.86b)
FCF Margin = 18.45% (FCF TTM 166.3m / Revenue TTM 901.1m)
Net Margin = 15.40% (Net Income TTM 138.8m / Revenue TTM 901.1m)
Gross Margin = 41.26% ((Revenue TTM 901.1m - Cost of Revenue TTM 529.3m) / Revenue TTM)
Gross Margin QoQ = 40.67% (prev 41.08%)
Tobins Q-Ratio = 4.97 (Enterprise Value 4.86b / Total Assets 978.3m)
Interest Expense / Debt = 3.41% (Interest Expense 205.0k / Debt 6.01m)
Taxrate = 26.06% (12.4m / 47.4m)
NOPAT = 105.5m (EBIT 142.7m * (1 - 26.06%))
Current Ratio = 3.22 (Total Current Assets 494.6m / Total Current Liabilities 153.4m)
Debt / Equity = 0.01 (Debt 6.01m / totalStockholderEquity, last quarter 702.5m)
Debt / EBITDA = -0.97 (Net Debt -201.7m / EBITDA 207.7m)
Debt / FCF = -1.21 (Net Debt -201.7m / FCF TTM 166.3m)
Total Stockholder Equity = 657.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.58% (Net Income 138.8m / Total Assets 978.3m)
RoE = 21.12% (Net Income TTM 138.8m / Total Stockholder Equity 657.0m)
RoCE = 17.29% (EBIT 142.7m / Capital Employed (Total Assets 978.3m - Current Liab 153.4m))
RoIC = 16.05% (NOPAT 105.5m / Invested Capital 657.0m)
WACC = 9.25% (E(5.06b)/V(5.07b) * Re(9.26%) + D(6.01m)/V(5.07b) * Rd(3.41%) * (1-Tc(0.26)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.19%
[DCF Debug] Terminal Value 77.30% ; FCFF base≈152.1m ; Y1≈187.6m ; Y5≈319.5m
Fair Price DCF = 152.8 (EV 4.30b - Net Debt -201.7m = Equity 4.50b / Shares 29.5m; r=9.25% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 30.74 | EPS CAGR: -39.78% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.93 | Revenue CAGR: 15.84% | SUE: 0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=+0.007 | Revisions Net=+0 | Analysts=8
EPS next Year (2026-12-31): EPS=5.42 | Chg30d=-0.005 | Revisions Net=-2 | Growth EPS=+12.7% | Growth Revenue=+8.3%
Additional Sources for BMI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle